Tag: CLTI

COVID-19

Letter from Seattle: Amid COVID-19 pandemic, time to act is long...

Amid the COVID-19 pandemic, Benjamin W Starnes and Niten Singh urge service chiefs across the USA to "act this minute" in order to conserve...

Interdisciplinary wound care teams are integral for CLTI patients’ care, ISET...

The 32nd International Symposium on Endovascular Therapy (ISET; 22–25 January, Hollywood, USA) had a particular focus on treating critical limb-threatening ischaemia (CLTI). In the...
Ramon Varcoe

New meta-analysis finds “no observed difference” in mortality between paclitaxel and...

February 2020 brings another paclitaxel device meta-analysis of randomised controlled trials in chronic limb-threatening ischaemia (CLTI) patients. Krystal Dinh (Westmead Hospital, Sydney, Australia) et...

Vascular surgeons and cardiologists respond to new meta-analysis of PCBs in...

Eminent vascular surgeons and interventional cardiologists including Kim Hodgson (Springfield, USA), Ramon Varcoe (Sydney, Australia) and Gary Ansel (Columbus, USA) give their thoughts on...

IR experts respond to new meta-analysis of paclitaxel-coated balloons in infrapopliteal...

 A range of interventional radiology experts including Michael Dake (Tucson, USA), John Kaufman (Portland, USA), Jim Reekers (Amsterdam, The Netherlands) and Gunnar Tepe (Rosenheim,...
vascular limb salvage clinic

Vascular limb salvage (VaLS) clinic helps to meet the VSGBI time-to-treatment...

Described as “deliberately challenging”, the new time-to-treatment targets published by the Vascular Society of Great Britain and Ireland (VSGBI), as part of the Peripheral...
LimFlow stent provides CLTI Patients relief

First CLTI patient enrolled in PROMISE II pivotal study of LimFlow...

LimFlow, a specialist in minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease (PAD), has announced...
limflow stent

LimFlow receives FDA approval for US study of minimally-invasive technology designed...

LimFlow has announced that the US Food and Drug Administration (FDA) has approved its investigational device exemption (IDE) for the PROMISE II pivotal study of...

New Global Vascular Guidelines for CLTI patients now open for stakeholder...

 The draft Global Vascular Guidelines on chronic limb threatening ischaemia (CLTI) have just been posted for open public comment until 3 December 2018. Michael...